Antibiotic API Raw Materials powder Fidaxomicin

CAS:873857-62-6

MF:C52H74Cl2O18

MW:1058.04

EINECS:/

Specification​: 99% min Fidaxomicin powder

Sample:Fidaxomicin powder

Packaging:1kg/bag, 25kg/drum

Brand: Henrikang

Appearance:white

Shelf Life: 2 Years

Test Method: HPLC

Fidaxomicin Powder Usage and Synthesis.

1. Regulation of intestinal microbial community

The intestinal microbiome is the sum total of various microorganisms that live in the human digestive tract. These microorganisms play an important role in the body's health and immune function. By selectively inhibiting the growth of specific pathogens, fedamycin can help restore and regulate the balance of the gut microbiome. This regulation can promote the growth of beneficial bacteria and inhibit the reproduction of harmful bacteria.

2. Inhibit the growth of pathogenic bacteria in the gut

Diarrhea is usually caused by an intestinal infection caused by certain bacteria. Fedamycin can highly selectively bind to these pathogenic bacteria and inhibit their growth and replication. It primarily targets the enterotoxin-producing bacterium Clostridium difficile (C. difficile), a strain often associated with diarrhea associated with antibiotic use.

3. Reduce the recurrence rate of diarrhea

After fedamycin treatment, the diarrhea recurrence rate was low because of its selective inhibition of C. difficile. This means that after treatment for the infection, patients are less likely to redevelop C. difficile related diarrhea symptoms.

4. Reduce the risk of antibiotic-associated diarrhea

Compared with other broad-spectrum antibiotics, fedamycin has more limited antibiotic activity, mainly targeting C. difficile bacteria. This makes patients taking fedamycin less likely to develop antibiotic-associated diarrhea (AAD). Antibiotic-associated diarrhea refers to a common side effect that occurs after the use of antibiotics and can further lead to serious intestinal complications.

Drug interaction of Fidaxomicin.

Fedamicin and its major metabolite, OP-1118, are substrates for P-glycoprotein efflux transporters, which are present in the GI tract. The interactions of fedamicin with P-glycoprotein substrates and their inhibitors, as well as with CYP450 isoenzymes 3A4, 2C9, and 2C19 have been evaluated. The drugs studied included cyclosporin, digoxin, midazolam, omeprazole and warfarin. Although the combination of cyclosporine and fedamicin nearly tripled the maximum blood concentration of fedamicin, these changes were not clinically significant because the concentration was still in the ng/mL range. There was no change in the pharmacokinetics of fedamicin in combination with the other drugs. According to current research, fedamicin does not need to be adjusted when drugs that alter P-glycoprotein efflux transporters and cytochrome P450 isoenzymes are used simultaneously.

Product Method of Bulk Fidaxomicin Powder.